EZH2 pathologic activation due to gain-of-function mutations and the associated increase in H3K27me3 at target genes have been clearly demonstrated to be essential for the development of germinal center derived B-cell lymphomas [51–54]. This evidence concerns the gene EZH2 and B-cell non-Hodgkin lymphoma.